CT-2106 for the Second Line Treatment of Ovarian Cancer

Exclusion Criteria

• •Platinum-sensitive patients (Group 2) who responded (CR or PR) to a 1st line therapy and subsequently progressed or relapsed after a treatment-free interval of \> 12 months
• •Pregnant or lactating patients
• •Prior treatment with camptothecins
• •Presence or history of CNS metastasis or carcinomatous leptomeningitis;
• •Current active infection per investigator assessment;
• •Unresolved bowel obstruction or subobstruction, uncontrolled Crohn's disease or ulcerative colitis;
• •Current history of chronic diarrhea \>= grade 1 (CTCAE version 3);
• •Surgery or radiotherapy ≤ 4 weeks before first study treatment. In case of cytoreductive surgery for the progression of the disease, ≤ 2 weeks before the 1st study treatment are allowed;
• •Other uncontrolled, serious illness or medical condition, as determined by the investigator;
• •Concomitant (or within 4 weeks before inclusion) administration of any other experimental drug under investigation;
• •Concurrent treatment with any other anti-cancer therapy;
• •Known HIV positivity or AIDS-related illness;
• •Patients who cannot be regularly followed up for psychological, social, familial or geographic reasons.